Free Trial

InspireMD Q4 2022 Earnings Report

InspireMD logo
$3.00 +0.02 (+0.67%)
(As of 12/20/2024 05:31 PM ET)

InspireMD EPS Results

Actual EPS
-$0.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

InspireMD Revenue Results

Actual Revenue
$1.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

InspireMD Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

InspireMD Earnings Headlines

InspireMD Finance Chief Craig Shore To Retire
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
InspireMD initiated with a Buy at Lake Street
See More InspireMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InspireMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InspireMD and other key companies, straight to your email.

About InspireMD

InspireMD (NYSE:NSPR), a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

View InspireMD Profile

More Earnings Resources from MarketBeat

Upcoming Earnings